financetom
Business
financetom
/
Business
/
PRESS DIGEST-Financial Times - Aug 6
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
PRESS DIGEST-Financial Times - Aug 6
Aug 5, 2024 8:51 PM

Aug 6 (Reuters) - The following are the top stories in

the Financial Times. Reuters has not verified these stories and

does not vouch for their accuracy.

Headlines

- Glencore ( GLCNF ) ordered to pay $152 million to resolve Swiss

bribery probe

- Mars in talks to buy $22 billion Pringles maker Kellanova ( K )

- Continental considers floating its core automotive

business

- Elon Musk files new lawsuit against OpenAI and Sam Altman

- EU capitals set to back tariffs on Chinese electric cars,

trade chief says

Overview

- Glencore ( GLCNF ) has been ordered by Swiss authorities to

pay about $152 million as a fine and compensation, resolving a

four-year investigation in relation to the alleged bribery of a

Congolese public official by a business partner in 2011.

- Mars, the candy, food and petcare conglomerate, is in

talks to buy Pringles and Pop-Tarts maker Kellanova ( K ), in

what would be one of the year's biggest takeovers.

- Continental is considering splitting the company

by listing its core automotive division, as one of Europe's

largest suppliers to the car industry continues to struggle with

stagnant demand in the sector.

- Elon Musk has filed a new lawsuit against OpenAI and its

chief executive Sam Altman, reviving his claim that the

artificial intelligence (AI) start-up he co-founded backtracked

on its mission to benefit humanity when it signed a commercial

partnership with Microsoft ( MSFT ).

- EU member states are likely to support the imposition of

proposed tariffs on Chinese electric vehicles in November,

according to Valdis Dombrovskis, the European commissioner for

trade.

(Compiled by Bengaluru newsroom)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Novo Nordisk Says FDA Approves Weight Loss Drug Wegovy HD
Novo Nordisk Says FDA Approves Weight Loss Drug Wegovy HD
Mar 19, 2026
12:13 PM EDT, 03/19/2026 (MT Newswires) -- Novo Nordisk ( NVO ) said Thursday the US Food and Drug Administration has approved its once-weekly Wegovy HD injection to lower excess body weight and sustain long-term weight loss. The accelerated approval was supported by late-stage trial data where the 7.2-milligram dose produced an average of 21% weight loss in obese participants,...
Actelis Networks (ASNS) Stock Is Surging Thursday: What's Driving The Action?
Actelis Networks (ASNS) Stock Is Surging Thursday: What's Driving The Action?
Mar 19, 2026
Actelis Networks Inc ( ASNS ) stock is trading higher Thursday, even after the company reported a wider-than-expected fourth-quarter loss, as investors appeared to focus on a sharp sequential revenue rebound, improving gross margin and an expanded share repurchase program. Here’s what investors need to know. Actelis Networks ( ASNS ) stock is charging ahead with explosive momentum. What’s behind...
Apple fends off bid for new Apple Watch import ban at US trade tribunal 
Apple fends off bid for new Apple Watch import ban at US trade tribunal 
Mar 19, 2026
WASHINGTON, March 19 (Reuters) - A U.S. trade tribunal preliminarily ruled that Apple's ( AAPL ) current Apple Watches do not infringe patents owned by Masimo ( MASI ), rejecting the medical-monitoring company's bid for a renewed import ban on the tech giant's smartwatches. Apple ( AAPL ) altered its watches to circumvent an import ban that the U.S. International...
Protagonist's Oral Peptide Platform Validated With Icotyde Approval for Psoriasis, Wedbush Says
Protagonist's Oral Peptide Platform Validated With Icotyde Approval for Psoriasis, Wedbush Says
Mar 19, 2026
12:10 PM EDT, 03/19/2026 (MT Newswires) -- Protagonist Therapeutics ( PTGX ) received further validation for its oral peptide platform with the US Food Drug Administration approval of Icotyde as treatment for psoriasis, Wedbush Securities said in a note Thursday. The investment firm said the regulatory approval was expected after Protagonist and partner Johnson & Johnson (JNJ), which holds global...
Copyright 2023-2026 - www.financetom.com All Rights Reserved